Roche drops Phase III plans for emugrobart in two muscle wasting diseases
The big pharma company will no longer progress emugrobart to late-stage trials in FSHD and SMA due to a lack of efficacy.
20 March 2026
20 March 2026
The big pharma company will no longer progress emugrobart to late-stage trials in FSHD and SMA due to a lack of efficacy.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.